Residual viremia in HIV-infected patients who continue a 2-drug or switch to a 3-drug integrase strand transfer inhibitor-based regimen.

In this randomized, single-center, open-label, 96-week, superiority, controlled trial of 50 HIV-infected patients with HIV-RNA <50 copies/mL on a two-drug regimen based on dolutegravir plus one reverse transcriptase inhibitor, switching to a single tablet regimen of cobicistat, elvitregravir, emtricitabine plus tenofovir alafenamide did not appear to mitigate the burden of residual viremia, both at week 48 and at week 96. The immunological changes observed during follow-up and the safety of the two regimens were similar.